JP2010513522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513522A5 JP2010513522A5 JP2009542922A JP2009542922A JP2010513522A5 JP 2010513522 A5 JP2010513522 A5 JP 2010513522A5 JP 2009542922 A JP2009542922 A JP 2009542922A JP 2009542922 A JP2009542922 A JP 2009542922A JP 2010513522 A5 JP2010513522 A5 JP 2010513522A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- antigen
- binding fragment
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 42
- 238000009472 formulation Methods 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 29
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 15
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 13
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 13
- 229940053128 nerve growth factor Drugs 0.000 claims 13
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 8
- 239000008351 acetate buffer Substances 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- 229940009098 aspartate Drugs 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 229940049906 glutamate Drugs 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 229920005862 polyol Polymers 0.000 claims 4
- 150000003077 polyols Chemical class 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 239000007853 buffer solution Substances 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 150000001510 aspartic acids Chemical class 0.000 claims 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000013923 monosodium glutamate Nutrition 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229940073490 sodium glutamate Drugs 0.000 claims 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87680106P | 2006-12-21 | 2006-12-21 | |
| US60/876,801 | 2006-12-21 | ||
| PCT/US2007/026060 WO2008079290A2 (en) | 2006-12-21 | 2007-12-19 | Stable buffered formulations containing polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013109920A Division JP2013216659A (ja) | 2006-12-21 | 2013-05-24 | ポリペプチドを含有する安定な緩衝化された製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513522A JP2010513522A (ja) | 2010-04-30 |
| JP2010513522A5 true JP2010513522A5 (enExample) | 2011-02-10 |
| JP5577098B2 JP5577098B2 (ja) | 2014-08-20 |
Family
ID=39563088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542922A Active JP5577098B2 (ja) | 2006-12-21 | 2007-12-19 | ポリペプチドを含有する安定な緩衝化された製剤 |
| JP2013109920A Pending JP2013216659A (ja) | 2006-12-21 | 2013-05-24 | ポリペプチドを含有する安定な緩衝化された製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013109920A Pending JP2013216659A (ja) | 2006-12-21 | 2013-05-24 | ポリペプチドを含有する安定な緩衝化された製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20080213282A1 (enExample) |
| EP (1) | EP2129401B8 (enExample) |
| JP (2) | JP5577098B2 (enExample) |
| AU (1) | AU2007338791B2 (enExample) |
| CA (2) | CA2790018C (enExample) |
| ES (1) | ES2748526T3 (enExample) |
| MX (1) | MX2009006594A (enExample) |
| WO (1) | WO2008079290A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| RU2481824C2 (ru) * | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EP2403873A1 (en) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| ES2514319T3 (es) * | 2009-05-04 | 2014-10-28 | Abbvie Research B.V. | Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada |
| JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
| SG176717A1 (en) * | 2009-06-12 | 2012-01-30 | Helsinn Therapeutics Us Inc | Ipamorelin diacetate injection and infusion solutions |
| EP2473528B1 (en) | 2009-09-03 | 2014-12-03 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| SI2523688T1 (en) * | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| BR112013025866A2 (pt) * | 2011-04-07 | 2016-12-20 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| AU2012326170B2 (en) | 2011-10-18 | 2016-12-22 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
| US9186295B2 (en) | 2011-10-25 | 2015-11-17 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| WO2014011629A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Stable aqueous formulations of etanercept |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| KR102250937B1 (ko) | 2012-09-11 | 2021-05-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717649B2 (en) * | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| GB2516808A (en) * | 2013-05-31 | 2015-02-11 | Innova Biosciences Ltd | Antibody composition and buffer system therefor |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| RS65120B1 (sr) * | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
| EP3434283A4 (en) * | 2016-03-25 | 2019-11-13 | Astellas Pharma Inc. | MEDICAL COMPOSITION WITH A FAB 'FRAGMENT OF A HUMAN ANTI-NGF ANTIBODY AGAINST PEG |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| PL3615066T3 (pl) * | 2017-04-28 | 2024-04-29 | Amgen Inc. | Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania |
| MA48461A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3749363A1 (en) * | 2018-02-08 | 2020-12-16 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| US20220008536A1 (en) * | 2018-11-16 | 2022-01-13 | Samsung Bioepis Co., Ltd. | Stable liquid composition comprising protein |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| WO2020216847A1 (en) * | 2019-04-23 | 2020-10-29 | Sanofi | Stable, low-viscosity antibody formulations and uses thereof |
| WO2021168133A1 (en) * | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| US12558423B2 (en) | 2020-05-29 | 2026-02-24 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
| US20220031812A1 (en) * | 2020-07-30 | 2022-02-03 | Silver Creek Pharmaceuticals, Inc. | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) * | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) * | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) * | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) * | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9108199D0 (en) * | 1991-04-17 | 1991-06-05 | Rhone Poulenc Agriculture | New compositions of matter |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AT400199B (de) * | 1993-10-11 | 1995-10-25 | Immuno Ag | Aufbereitung von lipoproteinhältigen proben |
| GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| KR100408229B1 (ko) * | 1996-10-04 | 2003-12-01 | 암겐 인코포레이티드 | Ｍｐｌ 리간드를 함유하는 제약학적 조성물 |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1391209A4 (en) * | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
| US20060024346A1 (en) * | 2004-07-29 | 2006-02-02 | Brody Richard S | Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| KR20050111598A (ko) * | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| WO2004084816A2 (en) * | 2003-03-21 | 2004-10-07 | Progenics Pharmaceuticals, Inc. | IMPROVED CD4-IgG2 FORMULATIONS |
| UA97086C2 (uk) * | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
| AU2004287879C1 (en) * | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| DK1543735T3 (en) * | 2003-12-20 | 2015-11-02 | Nestec Sa | FOOD COMPOSITION FOR HEALTH CARE |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| JP2006001912A (ja) * | 2004-06-21 | 2006-01-05 | Chugai Pharmaceut Co Ltd | タンパク質製剤の安定化方法 |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2008543839A (ja) * | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
-
2007
- 2007-12-19 EP EP07863175.1A patent/EP2129401B8/en active Active
- 2007-12-19 CA CA2790018A patent/CA2790018C/en active Active
- 2007-12-19 AU AU2007338791A patent/AU2007338791B2/en active Active
- 2007-12-19 MX MX2009006594A patent/MX2009006594A/es active IP Right Grant
- 2007-12-19 ES ES07863175T patent/ES2748526T3/es active Active
- 2007-12-19 WO PCT/US2007/026060 patent/WO2008079290A2/en not_active Ceased
- 2007-12-19 JP JP2009542922A patent/JP5577098B2/ja active Active
- 2007-12-19 CA CA2672902A patent/CA2672902C/en active Active
- 2007-12-19 US US12/004,114 patent/US20080213282A1/en not_active Abandoned
-
2013
- 2013-05-24 JP JP2013109920A patent/JP2013216659A/ja active Pending
-
2015
- 2015-05-05 US US14/704,853 patent/US20150315271A1/en not_active Abandoned
-
2019
- 2019-05-22 US US16/419,527 patent/US20190345238A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2672902A1 (en) | Formulations | |
| US20240238382A1 (en) | URI Agonist/Vasodilator | |
| CN102946861B (zh) | 浓缩蛋白制剂及其用途 | |
| JP5918246B2 (ja) | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 | |
| ES2688726T3 (es) | Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico | |
| JP6405406B2 (ja) | 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤 | |
| EA201200490A1 (ru) | Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения | |
| RU2012135384A (ru) | Стабилизированные содержащие антитела жидкие композиции | |
| JP2019536761A5 (enExample) | ||
| RU2015132431A (ru) | Составы, содержащие антитела | |
| JP2008515775A5 (enExample) | ||
| JP2012519695A5 (enExample) | ||
| JP2013521296A5 (enExample) | ||
| AR111497A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
| JP2013504589A5 (enExample) | ||
| RU2017101667A (ru) | Фармацевтические композиции | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| CN109563161A (zh) | 用于提高抗体稳定性的缓冲制剂 | |
| JP2016534052A5 (enExample) | ||
| JP2015517556A5 (enExample) | ||
| CN109803639A (zh) | 新制剂 | |
| Mirzazadeh et al. | Effects of drinking water quality on urinary parameters in men with and without urinary tract stones | |
| JP2022505290A (ja) | 安定性セマグルチド組成物およびその使用 | |
| CN105283170A (zh) | 包含肾上腺素和柠檬酸的可注射的药物组合物 | |
| JP2010536786A (ja) | ポリカチオンを用いた抗体およびｆｃ融合分子の製剤 |